Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer

•Patients’ perspectives are at the center of value-based oncology care.•Patient reported outcomes (PROs) guide clinical and regulatory decisions.•PRO instruments do not capture immune-related adverse events in clinical trials.•Studies did not accurately report PROs after treatment discontinuation.•Precise analyses of longitudinal effects of nivolumab on PROs were lacking.